Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immix Biopharma, Inc. (IMMX)

Immix Biopharma prices $125 million common stock offering at $11.00 per share

Neutral Impact 3 of 5 financing Written later

Immix Biopharma agreed on September 29, 2026 to sell 11,363,637 shares of common stock at $11.00 per share in an underwritten offering led by J.P. Morgan Securities LLC. The company expects gross proceeds of $125 million and net proceeds of approximately $117.1 million, with closing expected on September 30, 2026. The company plans to use the proceeds for NXC-201 development, working capital and general corporate purposes.

Key points

  • 11,363,637 shares priced at $11.00 per share under an underwriting agreement with J.P. Morgan Securities LLC dated September 29, 2026
  • Expected gross proceeds of $125 million and net proceeds of approximately $117.1 million after underwriting discounts, commissions and offering expenses
  • Offering expected to close on or about September 30, 2026, subject to customary conditions; proceeds to fund NXC-201 development, working capital and general corporate purposes

The filing

CompanyImmix Biopharma, Inc. (IMMX)
Form8-K, current report
Filed with the SECSep 30, 2026, 5:10 PM ET
Accession number0001493152-26-045143

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.